Chester County News and Community Website
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that it has been awarded a Group Purchasing Agreement with Premier …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that the Centers for Medicare and Medicaid Services (CMS) established a …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced a virtual poster presentation highlighting new Phase IIIb ANJESO® (meloxicam) injection …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that it has entered into a Pharmacy Supplier Agreement with Vizient, …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced a virtual poster presentation highlighting ANJESO™ (meloxicam) injection data at Digestive …
Read More MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced two virtual poster presentations highlighting new ANJESO™ (meloxicam) injection data at …
Read More
MALVERN, PA — Baudax Bio, Inc. (NASDAQ: BXRX), a pharmaceutical company focused on therapeutics for acute care settings, announced that ANJESO™ (meloxicam) injection, the only 24-hour, intravenous (IV) COX-2 preferential …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a pharmaceutical company with a high-performing, revenue-generating contract development and manufacturing (CDMO) segment and an Acute Care segment, reported financial results for the three and …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for hospitals and other acute care settings, announced the publication of clinical data from its Phase III …
Read More
MALVERN, PA — Recro Pharma, Inc. (NASDAQ: REPH), a revenue-generating specialty pharmaceutical company focused on therapeutics for the hospital and other acute care settings, reported financial results for the fourth quarter and year …
Read More